Also from Zacks Small Cap Research and John Vandermosten - Azitra Inc COO Travis Whitfill on ATR-12 https://lnkd.in/eHAt64np
Azitra Inc's COO Travis Whitfill Outlines What's Next for ATR-04 with Senior Analyst John Vandermosten
Azitra Inc
生物技术
Branford，Connecticut 1,965 位关注者
Precision dermatology powered by microbial and genetic engineering
关于我们
Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.
- 网站
-
https://www.azitrainc.com
Azitra Inc的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Branford，Connecticut
- 类型
- 私人持股
- 创立
- 2014
地点
-
主要
获取路线
21 Business Park Dr
US，Connecticut，Branford，06405
Azitra Inc员工
动态
-
Thanks John Vandermosten at Zacks Small Cap Research for speaking with Azitra Inc's COO Travis Whitfill about what's next for ATR-04
Azitra Inc's COO Travis Whitfill Outlines What's Next for ATR-04 with Senior Analyst John Vandermosten
Azitra's (AZTR) COO Travis Whitfill Outlines What's Next for ATR-04
https://www.youtube.com/
-
Azitra to Present at Microbiome Times Partnering Forum #dermatology #precisionderm #biotech https://lnkd.in/ejtfxmVg
-
More from Azitra Inc's Travis Whitfill on the DNA Today Podcast What led you to Co-Found Azitra? What need did you see? Check out the full episode here: https://lnkd.in/epGin9wR
-
ICYMI - Thanks Kira Dineen, MS, LCGC, CG(ASCP)CM of the DNA Today Podcast for speaking with Azitra Inc's COO Travis Whitfill - discussing our approach to #PrecisionDermatology powered by microbial & genetic engineering - Check out the full episode here: https://lnkd.in/etiCMG4t
-
More from our announcement yesterday - "Our lead product, ATR-12, is an engineered strain of?S. epidermidis?designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. In?August 2024, we initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients to assess multiple safety, tolerability, and efficacy endpoints. Initial safety data from this trial is expected in the first half of 2025 with topline results by year-end 2025." #NethertonSyndrome #biotech #dermatology $AZTR https://lnkd.in/esdb4Syn
-
-
More from today's announcement - We look forward to capitalizing on multiple value-building milestones during '25, including clinical data from our ATR-12 program. These events are expected to provide key inflection points for @azitrainc & investors throughout the year. #biotech #raredisease #PrecisionDerm $AZTR https://lnkd.in/esdb4Syn
-
-
Azitra Inc Announces Full Year 2024 Financial Results and Provides Business Updates https://lnkd.in/esdb4Syn
-
Azitra Inc转发了
Our team at Azitra is on fire lately! Last month, we announced the expansion of our patent portfolio and a $10 million financing. Earlier this week, we announced the screening of the first patient in our Phase 1b trial of ATR-12 for Netherton syndrome. And today, we're announcing the FDA has cleared our IND for a Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated skin rash. Proud of our team! Now we're focused on execution and clinical data. https://lnkd.in/eivD4Tcj
-
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome https://lnkd.in/eb2fzkQd